Cognition Therapeutics

Gold compound
#Alzheimer's #BioInnovation Institute #Biotech hubs #Cognition Therapeutics #India #Interview #Market reporting #Neurodegenerative disorders #Neuroscience #Pregnancy #Start-ups #Women's health

Podcast: Where are scientists making waves in drug discovery?

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting… Read More

#News

Neurodegenerative disorders
#Alzheimer's #Cognition Therapeutics #Interview #Neurodegenerative disorders #Neuroscience

How pharma is targeting advances in Alzheimer’s treatments

Listen to this article on the DDW Podcast: Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. Read More

#Exclusive Content